On Air Now

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 1230 AM Sioux Falls, SD 98.1 FM Sioux Falls, SD

Weather

Current Conditions(Sioux Falls,SD 57104)

More Weather »
72° Feels Like: 72°
Wind: S 0 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Partly Cloudy 66°

Tomorrow

Isolated Thunderstorms 86°

Sun Night

Partly Cloudy 62°

Alerts

GSK says melanoma combination meets main goal

LONDON (Reuters) - GlaxoSmithKline said on Friday the first of its phase three studies into the combination of Tafinlar and Mekinist to treat melanoma, the deadliest form of skin cancer, had met its main goal.

The results, along with further data expected from the study, will increase the body of evidence on the safety and efficiacy of the combination, the British company said.

The combined use of Tafinlar, also known as dabrafenib, and Mekinist, or trametinib, was given the green light from the Food and Drug Administration (FDA) in the U.S. earlier this month.

(Reporting by Kate Holton, Editing by Paul Sandle)

Comments